01 January 2015

Effect of 3- and 6-month treatment with either acetazolamide (ACZ) or placebo on pulmonary vascular resistance and pulmonary acceleration time in CMS patients

AI00162.jpg
Richalet J-P,Rivera M,Maignan M,Pham I,Privat C,Leon-Velarde F.Pulmonary hypertension and monges disease. [Internet]. 2009 ;1:114. Available from:http://www.pvrireview.org/text.asp?2009/1/2/114/50730

Effect of 3- and 6-month treatment with either acetazolamide (ACZ) or placebo on pulmonary vascular resistance and pulmonary acceleration time (as an inverse index of pulmonary resistance) in a group of CMS patients.

 

Additional keywords: acetazolamide,chronic mountain sickness,PAAT

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg